SANDPIPER III期研究:他塞利布联合氟维司群治疗PIK3CA突变晚期乳腺癌
SANDPIPER III期随机研究评估他塞利布(PI3K抑制剂)联合氟维司群用于雌激素受体阳性、HER2阴性、PIK3CA突变的局部晚期或转移性乳腺癌。结果显示他塞利布组研究者评估的无进展生存期显著改善(7.4个月 vs 5.4个月,HR 0.70,P=0.0037),但严重不良事件和停药率更高,临床获益有限,无临床实用性。
要点
- 他塞利布联合氟维司群显著延长PIK3CA突变患者INV-PFS(7.4 vs 5.4个月,HR 0.70)。
- 他塞利布组严重不良事件(32.0% vs 8.9%)和停药率(16.8% vs 2.3%)更高。
- 尽管达到主要终点,但安全性差且获益有限,联合方案无临床实用性。
核心结论
- SANDPIPER研究达到主要终点,但他塞利布联合氟维司群因安全性及获益有限无临床实用性。
研究设计与样本
- III期随机研究纳入绝经后雌激素受体阳性、HER2阴性、PIK3CA突变晚期乳腺癌患者,按2:1随机接受他塞利布(4 mg)或安慰剂联合氟维司群(500 mg)。
- PIK3CA突变意向治疗人群共516例(安慰剂组176例,他塞利布组340例),主要终点为研究者评估的无进展生存期(INV-PFS)。
主要发现
- 他塞利布组INV-PFS为7.4个月(95%CI 7.26-9.07),安慰剂组为5.4个月(95%CI 3.68-7.29),分层HR 0.70(95%CI 0.56-0.89,P=0.0037)。
- 盲法独立中心评估的PFS证实获益(HR 0.66)。
- 客观缓解率、临床获益率和缓解持续时间在他塞利布组显示一致改善。
关键数值与推荐
- 安全性分析纳入所有至少接受一剂研究药物的随机患者(n=629),他塞利布组严重不良事件发生率为32.0%,安慰剂组为8.9%。
- 他塞利布组停药率为16.8%(安慰剂组2.3%),剂量降低率为36.5%(安慰剂组2.3%)。
临床怎么用
- 他塞利布联合氟维司群不推荐用于PIK3CA突变晚期乳腺癌的临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase III SANDPIPER study assessed taselisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally advanced or metastatic breast cancer. PATIENTS AND METHODS: Postmenopausal women with disease recurrence/progression during/after an aromatase inhibitor were randomized 2 : 1 to receive taselisib (4 mg; taselisib arm) or placebo (placebo arm) plus fulvestrant (500 mg). Stratification factors were visceral disease, endocrine sensitivity, and geographic region. Patients with PIK3CA-mutant tumors (central cobas® PIK3CA Mutation Test) were randomized separately from those without detectable mutations. The primary endpoint was investigator-assessed progression-free survival (INV-PFS) in patients with PIK3CA-mutant tumors. Secondary endpoints included objective response rate, overall survival, clinical benefit rate, duration of objective response, PFS by blinded independent central review (BICR-PFS), safety, and time to deterioration in health-related quality of life. RESULTS: The PIK3CA-mutant intention-to-treat population comprised 516 patients (placebo arm: n = 176; taselisib arm: n = 340). INV-PFS was significantly improved in the taselisib {7.4 months [95% confidence interval (CI), 7.26-9.07]} versus placebo arm (5.4 months [95% CI, 3.68-7.29]) (stratified hazard ratio [HR] 0.70; 95% CI, 0.56-0.89; P = 0.0037) and confirmed by BICR-PFS (HR 0.66). Secondary endpoints, including objective response rate, clinical benefit rate, and duration of objective response, showed consistent improvements in the taselisib arm. Safety was assessed in all randomized patients who received at least one dose of taselisib/placebo or fulvestrant regardless of PIK3CA-mutation status (n = 629). Serious adverse events were lower in the placebo versus taselisib arm (8.9% versus 32.0%). There were more discontinuations (placebo arm: 2.3%; taselisib arm: 16.8%) and dose reductions (placebo arm: 2.3%; taselisib arm: 36.5%) in the taselisib arm. CONCLUSION: SANDPIPER met its primary endpoint; however, the combination of taselisib plus fulvestrant has no clinical utility given its safety profile and modest clinical benefit.
引用
- Dent S, Cortés J, Im YH, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. 2020. PMID: 33186740. doi:10.1016/j.annonc.2020.10.596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。